Hyperuricemia Pipeline Shows Promise with 15+ Emerging Therapies in Development
核心洞察
Global hyperuricemia (搜索) pipeline comprises 12+ key companies developing 15+ treatment therapies across various clinical stages, according to DelveInsight's 2025 report.
Leading companies in hyperuricemia (搜索) drug development include LG Chem (搜索), Shanton Pharma (搜索), InventisBio, Jiangsu HengRui Medicine, and Selecta Biosciences, with treatments spanning oral, intravenous, and subcutaneous administration routes.
A significant development occurred in December 2024 when Atom Therapeutics (搜索) partnered with China Medical System Holdings (搜索) to commercialize lingdolinurad (ABP-671), a novel URAT1 (搜索) inhibitor for chronic gout (搜索) and hyperuricemia (搜索) in China.
The global hyperuricemia (搜索) treatment landscape is poised for significant expansion with 12+ pharmaceutical companies actively developing more than 15 novel therapies, according to a comprehensive pipeline analysis by DelveInsight.
Hyperuricemia (搜索), characterized by elevated levels of uric acid in the blood, can lead to painful conditions like gout (搜索) and kidney stones (搜索). The condition occurs when the body either produces excess uric acid or the kidneys fail to excrete it properly, often resulting from genetic predisposition, high-purine diets, obesity, certain medications, or underlying health conditions.
Robust Pipeline Across Multiple Development Stages
The current hyperuricemia (搜索) pipeline includes therapies in various stages of development, from preclinical to late-stage clinical trials. Key drug candidates include:
- Tigulixostat (LC350189) from LG Chem
- SAP-001 developed by Shanton Pharma
- D-0120 from InventisBio Co., Ltd
- SHR4640 by Jiangsu HengRui Medicine Co., Ltd.
- FYU-981 from Fuji Yakuhin Co., Ltd.
- SEL-212 by Selecta Biosciences, Inc.
These emerging therapies employ various administration routes, including oral, intravenous, subcutaneous, parenteral, and topical applications, providing potential flexibility in treatment options for patients.
Strategic Industry Collaborations
A notable development in the hyperuricemia (搜索) space occurred in December 2024 when Atom Therapeutics (搜索) Co. Ltd entered into an exclusive commercialization agreement with China Medical System Holdings (搜索) Ltd (CMS). This partnership grants CMS rights to commercialize lingdolinurad (ABP-671), a novel oral URAT1 (搜索) inhibitor for chronic gout (搜索) and hyperuricemia, across mainland China, Hong Kong, and Macao.
Such strategic collaborations highlight the growing industry interest in addressing the unmet needs in hyperuricemia (搜索) management.
Diverse Therapeutic Approaches
The pipeline features diverse molecular approaches to treating hyperuricemia (搜索), including:
- Small molecules
- Recombinant fusion proteins
- Monoclonal antibodies
- Peptides
- Polymers
- Gene therapies
This diversity in therapeutic approaches reflects the complex pathophysiology of hyperuricemia (搜索) and the multiple potential intervention points in uric acid metabolism.
Market Drivers and Challenges
Several factors are driving growth in the hyperuricemia (搜索) treatment market, including increasing disease prevalence, an aging global population, advancements in drug development technologies, improved diagnostic techniques, and rising awareness among healthcare providers and patients.
However, the market faces challenges such as high treatment costs, medication side effects, stringent regulatory requirements, limited awareness in developing regions, patent expirations, and lengthy drug development timelines.
Clinical Development Landscape
DelveInsight's analysis categorizes the pipeline products across different development phases:
- Late-stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage products (Phase I)
- Pre-clinical and discovery stage candidates
The report also tracks discontinued and inactive candidates, providing a comprehensive view of the development landscape.
Key Industry Players
Beyond the companies developing novel therapies, the broader hyperuricemia (搜索) market includes established pharmaceutical companies such as Pfizer Inc, F. Hoffmann-La Roche Ltd, Novartis AG, Teva Pharmaceutical Industries Ltd., Bayer AG, Bristol Myers Squibb, GSK Plc, and Sun Pharmaceutical Industries Ltd.
These companies contribute to the competitive landscape through their existing hyperuricemia (搜索) treatments or related pipeline assets.
Future Outlook
As the global prevalence of hyperuricemia (搜索) and related conditions like gout (搜索) continues to rise, driven by lifestyle factors and aging populations, the need for more effective and tolerable treatments remains significant.
The diverse pipeline of therapies in development suggests that patients and healthcare providers may soon have access to new treatment options with potentially improved efficacy, safety profiles, and convenience compared to current standard-of-care medications.
The continued investment in hyperuricemia (搜索) research and development by pharmaceutical companies underscores the recognized medical need and market opportunity in this therapeutic area.